TScan Therapeutics, Inc. (TCRX) announced the pricing of an underwritten public offering of 2,472,581 shares of voting common stock at a public offering price of the market price of $7.1300 per share, and pre-funded warrants to purchase up to an aggregate of 18,577,419 shares of voting common stock at a price to the public of $7.1299 per pre-funded warrant to purchase one share of the voting common stock. The gross proceeds to TScan are expected to be approximately $150.1 million. The offering is expected to close on or about April 19, 2024.
The company plans to use the net proceeds for general corporate purposes. Following the offering, the company expects existing cash, cash equivalents and marketable securities will enable it to fund operating expenses and capital expenditure requirements into the fourth quarter of 2026.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.